

Minimum Residual Disease (MRD)

TEST OFFERINGS

Minimal residual disease (MRD) findings strongly correlate with clinical outcomes in the posttherapy setting and provide clinicians with actionable data to help them determine whether to end or escalate therapy. ARUP has developed a variety of MRD tests based on specific clinical indications, and these tests offer excellent sensitivity.

Sending your MRD testing to ARUP ensures that you have access to a broad menu of oncology testing to aid in the diagnosis and treatment of your patients, as well as consistent reporting and expert consultations from top industry medical directors and scientists.

ARUP now has three flow cytometry test options:

- B-Cell Acute Lymphocytic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry (COG Protocol)
- Multiple Myeloma Minimum Residual Disease by Flow Cytometry
- Chronic Lymphocytic Leukemia Minimum Residual Disease by Flow Cytometry



Learn more about all of our
MRD test options:
aruplab.com/MRD